Still hungry in the first week of Wegovy — what the evidence says

What the trial data tells us about the first week

The STEP 1 trial followed 1,961 adults with obesity over 68 weeks and found an average body-weight reduction of around 15% in the semaglutide group. But those results accumulated over more than a year of treatment, with the dose rising in four-week steps from 0.25mg through to the 2.4mg maintenance level. There is no data from that trial suggesting substantial appetite suppression in week one, because the starting dose was never intended to produce it. The trial design itself encodes the expectation that week one is about tolerability, not transformation.

Semaglutide works as a GLP-1 receptor agonist, it mimics a gut hormone that signals fullness to the brain and slows how quickly food leaves the stomach. Those effects are dose-dependent. At 0.25mg, they are present only weakly. The NHS semaglutide medicines page confirms this gradual titration approach, noting that the dose increases help manage tolerability before therapeutic effect.

So if you are in your first week of Wegovy and still hungry, you are not in a minority. You are in the majority. What is likely to change is the trajectory over the coming months as the dose climbs.

Why the starter dose works this way

The first pen's purpose is adjustment. Starting at a low dose reduces the likelihood of the nausea, vomiting and stomach discomfort that can otherwise hit hard when semaglutide is introduced at a higher level. For many people this trade-off is worth it, they tolerate treatment better and stay on it longer, which is what produces results.

Each dose level runs for a minimum of four weeks before moving up, meaning the full appetite-suppressing effect builds across roughly 16 weeks of titration. You can read more about what the early weeks typically look like on our first week of Wegovy page. Many people report the appetite shift becoming noticeable somewhere between weeks four and eight, often coinciding with the move to the 0.5mg or 1mg level. Some notice it earlier; a small number take longer. There is genuine individual variation.

One thing worth noting: hunger and appetite are not quite the same thing. Some people on semaglutide find physical hunger persists for longer than expected, but that they feel satisfied sooner when they do eat. That satiety signal (getting full faster at meals) is often the first change people notice, even when background hunger has not yet dropped dramatically.

Practical things that can help in the early weeks

Because the medicine is doing light work in week one, what you eat and when still matters a great deal. Protein and fibre tend to blunt hunger more than refined carbohydrates at any dose level. Eating at regular intervals (rather than waiting until hunger becomes urgent) helps many people manage the gap before appetite suppression kicks in properly. Staying well hydrated is worth more than it sounds; thirst is frequently mistaken for hunger.

It is also honest to say that this early period can feel discouraging. You started treatment hoping things would shift, and they have not yet. That frustration is real, and it does not reflect badly on you or the medicine. The timeline for Wegovy to take effect is longer than most people expect, and understanding that upfront makes the first weeks easier to sit with.

If hunger feels genuinely unbearable or you have any symptoms that worry you, contact your prescriber directly rather than waiting for a scheduled check-in. Wegovy is dispensed on prescription and comes with clinical support for exactly this reason. You can also explore how the first month typically unfolds on our first month of Wegovy page, which covers what changes to look out for as the dose rises.

When to expect appetite change, and what the evidence says about results

Looking at the broader picture: the STEP 1 trial's ~15% average weight reduction over 68 weeks gives a realistic benchmark. That figure includes the early weeks of low-dose treatment where very little is happening on the appetite front. Research into first-week results on Wegovy consistently shows that early weight change is modest and mostly reflects water and glycogen shifts rather than fat loss. Meaningful, sustained loss arrives later.

The titration schedule (0.25mg, then 0.5mg, then 1mg, then 1.7mg, then 2.4mg (and now up to 7.2mg for some patients following the MHRA's 2026 approval of a higher-dose pen)) is deliberately slow. Clinicians and the manufacturer designed it that way because long-term adherence produces better outcomes than a fast start followed by side-effect-driven discontinuation.

If you are considering starting treatment or have questions about whether Wegovy is right for you, our Wegovy overview covers the full picture, including eligibility and what a private prescription involves. For anyone weighing up cost as part of their decision, our Wegovy cost guide explains what honest pricing for a prescription medicine actually includes. And if you want to understand your treatment options more broadly, our weight-loss treatments page is a good place to start. A prescriber, not an algorithm, reviews every consultation at nume the same day it arrives.